Published in Ugeskr Laeger on August 24, 1981
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. Mult Scler (2013) 5.40
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology (2006) 2.24
Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien) (1990) 1.88
Essential tremor treated with propranolol: lack of correlation between clinical effect and plasma propranolol levels. Ann Neurol (1981) 1.75
Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke (1988) 1.74
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology (2009) 1.59
Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Mult Scler (2009) 1.56
Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler (2008) 1.49
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens (2004) 1.47
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler (2008) 1.42
Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. Int J Radiat Oncol Biol Phys (2000) 1.37
Bone lesions in early syphilis detected by bone scintigraphy. Br J Vener Dis (1984) 1.35
EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol (2005) 1.20
Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol (2000) 1.14
Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology (2000) 1.13
The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes Immun (2001) 1.11
Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke (1988) 1.10
Cerebral blood flow in patients with normal-pressure hydrocephalus before and after shunting. J Neurosurg (1987) 1.10
Intracranial pressure and cerebrospinal fluid outflow conductance in healthy subjects. J Neurosurg (1991) 1.09
Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. Acta Neurol Scand (2012) 1.05
The six spot step test: a new measurement for walking ability in multiple sclerosis. Mult Scler (2006) 1.05
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Mult Scler (2013) 1.03
The incidence and clinical presentation of neurosyphilis in Greater Copenhagen 1974 through 1978. Acta Neurol Scand (1981) 1.01
Familial effects on the clinical course of multiple sclerosis. Neurology (2007) 1.00
High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus. J Neurol Sci (1985) 0.97
Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. Eur J Cancer (1994) 0.95
The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Mult Scler (2006) 0.94
Correlations of brain MRI parameters to disability in multiple sclerosis. Acta Neurol Scand (2001) 0.93
Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J Neurol Neurosurg Psychiatry (1985) 0.91
The diagnostic reliability of magnetically evoked motor potentials in multiple sclerosis. Neurology (1992) 0.91
Cerebrospinal fluid vasopressin and increased intracranial pressure. Ann Neurol (1984) 0.90
Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult Scler (2000) 0.87
Prediction of response to interferon therapy in multiple sclerosis. Acta Neurol Scand (2014) 0.87
Long-term prognosis after transient ischemic attacks. Acta Neurol Scand (1981) 0.87
Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand (2000) 0.87
Measurement of blood flow in the superior sagittal sinus in healthy volunteers, and in patients with normal pressure hydrocephalus and idiopathic intracranial hypertension with phase-contrast cine MR imaging. Acta Radiol (1996) 0.85
Resistance to cerebrospinal fluid outflow and intracranial pressure in patients with hydrocephalus after subarachnoid haemorrhage. Acta Neurochir (Wien) (1987) 0.85
Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue. Acta Neurol Scand (2011) 0.85
Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir (Wien) (1987) 0.84
Assessment of CSF dynamics and venous flow in the superior sagittal sinus by MRI in idiopathic intracranial hypertension: a preliminary study. Neuroradiology (1994) 0.84
Cerebrospinal fluid flow and production in patients with normal pressure hydrocephalus studied by MRI. Neuroradiology (1994) 0.84
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Mult Scler (2012) 0.84
Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis. Genes Immun (2009) 0.83
Transient ischaemic attacks in young patients: a thromboembolic or migrainous manifestation? A 10 year follow up study of 46 patients. J Neurol Neurosurg Psychiatry (1990) 0.83
FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis. Clin Exp Immunol (2012) 0.83
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients. Eur J Neurol (2012) 0.82
Increased brain water self-diffusion in patients with idiopathic intracranial hypertension. AJNR Am J Neuroradiol (1995) 0.82
CSF-amine metabolites in depression, dementia and in controls. Acta Psychiatr Scand (1987) 0.82
Cerebral metabolism in a case of multiple sclerosis with acute mental disorder. Acta Neurol Scand (1996) 0.81
Metastatic spinal cord compression secondary to lung cancer. J Clin Oncol (1992) 0.81
Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level? Acta Neurochir (Wien) (1988) 0.81
Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol (2007) 0.81
Vasopressin in the cerebrospinal fluid of patients with normal pressure hydrocephalus and benign intracranial hypertension. Acta Endocrinol (Copenh) (1982) 0.81
Gender effects on treatment response to interferon-beta in multiple sclerosis. Acta Neurol Scand (2014) 0.80
The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Mult Scler (2000) 0.80
Diagnostic value of spinal computer tomography in patients with intraspinal metastases causing complete block on myelography. Acta Radiol (1991) 0.80
Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. Int J Radiat Oncol Biol Phys (1995) 0.80
CSF and plasma vasopressin concentrations in dementia. J Neurol Neurosurg Psychiatry (1983) 0.80
A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology (1999) 0.80
[Metastatic spinal compression syndrome. Symptoms, diagnosis, treatment and prognosis]. Ugeskr Laeger (1990) 0.79
A case of malignant lymphoma and myasthenia gravis. Scand J Haematol (1983) 0.79
Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. Mult Scler (2011) 0.79
Sexual dysfunction in male and female patients with epilepsy: a study of 86 outpatients. Arch Sex Behav (1990) 0.79
Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. Acta Neurol Scand (1986) 0.79
Visual evoked potentials in pseudotumor cerebri. Arch Neurol (1985) 0.79
High dose antioxidant supplementation to MS patients. Effects on glutathione peroxidase, clinical safety, and absorption of selenium. Biol Trace Elem Res (1990) 0.79
A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia (1986) 0.78
A variant form of metachromatic leucodystrophy in a patient suffering from another congenital degenerative neurological disease. Acta Neurol Scand (1985) 0.78
Studies of vasopressin in the human cerebrospinal fluid. Acta Neurol Scand (1986) 0.78
Increased self-diffusion of brain water in hydrocephalus measured by MR imaging. Acta Radiol (1994) 0.77
Severe headache as the only symptom of long-standing shunt dysfunction in hydrocephalic children with normal or slit ventricles revealed by computed tomography. Childs Nerv Syst (1985) 0.77
Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal. J Neurooncol (1992) 0.77
Sympathetic vasoconstrictor responses in multiple sclerosis with thermo-regulatory dysfunction. Clin Auton Res (1997) 0.77
Therapeutic interference with leukocyte recirculation in multiple sclerosis. Eur J Neurol (2015) 0.77
Vasopressin release during electroconvulsive therapy. Psychoneuroendocrinology (1982) 0.77
Vasopressin in plasma and ventricular cerebrospinal fluid during dehydration, postural changes, and nausea. Am J Physiol (1985) 0.77
Evaluation of electronic equipment for quantitative registration of tremor. Acta Neurol Scand (1998) 0.77
Cerebrospinal fluid vasopressin in benign intracranial hypertension. Neurology (1982) 0.77
[Sleep apnea]. Nord Med (1989) 0.77
A prospective PET study of patients with glioblastoma multiforme. Acta Neurol Scand (2006) 0.76
Low cerebrospinal fluid concentration of brain-specific protein D2 in patients with normal pressure hydrocephalus. J Neurol Sci (1983) 0.76
No linkage or association of the nitric oxide synthase genes to multiple sclerosis. J Neuroimmunol (2001) 0.76
MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler (2005) 0.76
Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Mult Scler (2006) 0.76
[Neurogenic bladder disturbances--who is to treat and follow-up the patients?]. Ugeskr Laeger (2001) 0.75
[Preventive drug therapy of transient cerebral ischemic attacks]. Ugeskr Laeger (1982) 0.75
[Aphasia following cerebral apoplexy. Neuropsychological and neurological symptoms]. Ugeskr Laeger (1979) 0.75
[Mortality and functional restoration in cerebral apoplexy. A review of 129 patients with apoplexy admitted as emergencies to a neuromedical department in Copenhagen in the course of a year]. Ugeskr Laeger (1980) 0.75
Steady state kinetics of pyridostigmine in myasthenia gravis. Neurology (1984) 0.75
[Hypokalemic paresis]. Ugeskr Laeger (1978) 0.75
[Social consequences of cerebral apoplexy. A review of 129 patients with cerebral apoplexy admitted as emergencies to a neuromedical department in Copenhagen in the course of a year]. Ugeskr Laeger (1980) 0.75
Cerebrospinal fluid and plasma vasopressin during short-time induced intracranial hypertension. Acta Neurochir (Wien) (1985) 0.75
[Neurosyphilis in Greater Copenhagen during the 5-year period 1974-1978]. Ugeskr Laeger (1981) 0.75
[Cerebral apoplexy prevention]. Nord Med (1982) 0.75
24-hour cerebrospinal fluid levels of vasopressin in hydrocephalic patients. Regul Pept (1985) 0.75
[Allergic alveolitis caused by a contaminating humidifier]. Ugeskr Laeger (1979) 0.75
Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. Eur J Clin Invest (1984) 0.75
Cerebrospinal fluid vasopressin as a marker of central nervous system metastases from small-cell bronchogenic carcinoma. J Clin Oncol (1985) 0.75